# Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care

> **NCT01163916** · — · COMPLETED · sponsor: **Abbott** · enrollment: 252 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01163916
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2012-12-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01163916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01163916, "Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01163916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*